Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle

University of Copenhagen

Status: Completed

Conditions: Insulin Resistance

Treatments: Dietary Supplement: MitoQ; Drug: Intralipid, 20% Intravenous Emulsion; Drug: Salbutamol

Study type: Interventional

Funder types: Other

Identifiers

NCT04558190

mtROS-IR

Details and patient eligibility

About

The purpose of the study is to evaluate the link between insulin resistance and alterations in skeletal muscle mitochondrial redox homeostasis

Enrollment: 10 patients

Sex: Male

Ages: 40 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body mass index (BMI) ≥25 and <40 kg/m2
• Fasting plasma glucose ≥ 5.6 mmol/L or HbA1c ≥ 5.7%
• HOMA2-IR > 1.4
• VO2max <45 ml/kg/min

Exclusion criteria

• Treatment with >2 antidiabetic medications
• Insulin usage
• Chronic disease deemed by the study responsible medical doctor to interfere with any part of the study
• Chronic use of prescription medicine deemed by the study responsible medical doctor to interfere with any part of the study
• Smoking

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

10 participants in 4 patient groups, including a placebo group

Lipid infusion + MitoQ

Experimental group

Description:

Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by MitoQ administration and intravenous lipid infusion

Treatment:

Drug: Intralipid, 20% Intravenous Emulsion

Dietary Supplement: MitoQ

Lipid infusion + placebo

Placebo Comparator group

Description:

Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by placebo administration and intravenous lipid infusion

Treatment:

Drug: Intralipid, 20% Intravenous Emulsion

Control

No Intervention group

Description:

Subjects undergo a hyperinsulinemic isoglycemic clamp

Lipid infusion + beta2-agonist

Other group

Description:

Subjects undergo a hyperinsulinemic isoglycemic clamp with intravenous infusion of lipid and salbutamol

Treatment:

Drug: Salbutamol

Drug: Intralipid, 20% Intravenous Emulsion